- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01967160
Osteonecrosis of the Jaw (ONJ) and Infection Among Nordic Cancer Patients Treated With XGEVA™ or Zoledronic Acid
June 20, 2023 updated by: Amgen
A Non-interventional Pharmacovigilance Study of Osteonecrosis of the Jaw and Infection Leading to Hospitalization Among Patients With Cancer Treated With XGEVA™ or Zoledronic Acid in Sweden, Denmark, and Norway
A non-interventional study to assess incident rates of Osteonecrosis of the Jaw and Infections leading to hospitalization in Cancer patients treated with XGEVA™ in Sweden, Denmark and Norway.
Study Overview
Status
Completed
Study Type
Observational
Enrollment (Actual)
2560
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Probability Sample
Study Population
Cancer patients treated with antiresorptive therapies for SRE prevention
Description
Inclusion Criteria:
- ≥ 18 years old
- diagnosed with cancer
- subsequent to cancer diagnosis, initiating cancer-related antiresorptive treatment during the treatment cohort identification period with XGEVA or zoledronic acid or switching to XGEVA from cancer-related treatment with oral or IV bisphosphonates at the dose indicated for SRE prevention of less than 2 years duration (≤ 24 IV infusions or ≤ 24 monthly oral prescriptions)
Exclusion Criteria:
- history of radiation treatment for head and neck cancer before a subject's potential index date
- hypercalcemia of malignancy as the sole indication for treatment with an anti-resorptive agent
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
XGEVA inception cohort
Patients with cancer who are naïve to oral or IV bisphosphonate treatment at the dose indicated for SRE prevention and who begin treatment with XGEVA at any time during the treatment cohort identification period
|
Zoledronic acid inception cohort
Patients with cancer who are naïve to oral or IV bisphosphonate treatment at the dose indicated for SRE prevention and who begin treatment with IV zoledronic acid at any time during the treatment cohort identification period
|
XGEVA-switch cohort
Patients with cancer who switch to XGEVA during treatment cohort identification period after having started antiresorptive therapy at the dose indicated for SRE prevention of no more than 2 years duration with bisphosphonates (<24 IV infusions or <24 monthly oral prescriptions)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
1. Incidence proportions of medically confirmed osteonecrosis of the jaw (ONJ) in XGEVA and zoledronic acid inception cohorts
Time Frame: 5 years
|
5 years
|
2. Incidence proportions of infections leading to hospitalization in XGEVA and zoledronic acid inception cohorts
Time Frame: 3 years
|
3 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
1. Incidence proportions of medically confirmed ONJ in the cohort switching from an oral or IV bisphosphonate (at the dose indicated for cancer patients to prevent skeletal related events) to XGEVA
Time Frame: 5 years
|
5 years
|
2. Incidence proportions of medically confirmed ONJ in the cohort switching from an oral or IV bisphosphonate (at the dose indicated for cancer patients to prevent SREs) to XGEVA stratified by number of prior cancer-related bisphosphonate treatments
Time Frame: 5 years
|
5 years
|
3. Characterize the XGEVA inception, zoledronic acid inception, and the XGEVA-switch cohorts with respect to patient characteristics, cancer type, medical history, and number of bisphosphonate or XGEVA treatments at the dose indicated for SRE prevention
Time Frame: 5 years
|
5 years
|
4. Summarize oral risk factor information for medically confirmed ONJ cases
Time Frame: 5 years
|
5 years
|
5. Summarize for medically confirmed ONJ cases information on ONJ stage, treatment, clinical course, and resolution
Time Frame: 5 years
|
5 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 2, 2012
Primary Completion (Actual)
August 5, 2019
Study Completion (Actual)
August 5, 2019
Study Registration Dates
First Submitted
October 18, 2013
First Submitted That Met QC Criteria
October 18, 2013
First Posted (Estimated)
October 22, 2013
Study Record Updates
Last Update Posted (Actual)
June 22, 2023
Last Update Submitted That Met QC Criteria
June 20, 2023
Last Verified
September 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20101363
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.
IPD Sharing Time Frame
Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities.
There is no end date for eligibility to submit a data sharing request for this study.
IPD Sharing Access Criteria
Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s).
In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling.
Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel.
Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement.
This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications.
Further details are available at the link below.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteonecrosis of the Jaw
-
Fundació d'investigació Sanitària de les Illes...RecruitingOsteonecrosis of the Jaw, Bisphosphonate Induced | Osteonecrosis of the Jaw, Bisphosphonate RelatedSpain
-
University of WashingtonUniversity of Alabama at Birmingham; University of Michigan; New York Center...Enrolling by invitationAvascular Necrosis | Medication-related Osteonecrosis of the Jaw | Bisphosphonate-related Osteonecrosis of the JawUnited States
-
AO Clinical Investigation and Publishing DocumentationAOCMFActive, not recruitingBisphosphonate-Associated Osteonecrosis of the Jaw | Medication-related Osteonecrosis of the JawGermany, Qatar, Switzerland, Finland, United States, Slovenia, Spain, Netherlands, Romania, Korea, Republic of
-
Micromedic Technologies LtdUnknownBisphosphonate-related Osteonecrosis of the JawIsrael
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnMalignant Neoplasm | Musculoskeletal ComplicationsUnited States
-
AmgenCompletedOsteonecrosis of the JawFrance, Germany, Italy, United States, Belgium, United Kingdom, Spain, Greece, Canada, Denmark, Finland
-
Dental Practice-Based Research NetworkNational Institute of Dental and Craniofacial Research (NIDCR); HealthPartners... and other collaboratorsCompleted
-
Medical University of GrazEnrolling by invitation
-
Dental Practice-Based Research NetworkNational Institute of Dental and Craniofacial Research (NIDCR); HealthPartners... and other collaboratorsCompleted
-
University of PalermoCompletedMEDICATION RELATED OSTEONECROSIS OF THE JAWItaly